Extracellular matrix remodeling in atrial fibrosis: mechanisms and implications in atrial fibrillation.

[1]  W. Guy Hood,et al.  STUDIES ON THE METABOLIC EFFECTS OF SPIRONOLACTONE IN MAN * , 1960, Annals of the New York Academy of Sciences.

[2]  V. Ferrans,et al.  Left atrial ultrastructure in mitral valvular disease. , 1977, The American journal of pathology.

[3]  J. S. Janicki,et al.  Remodeling of the rat right and left ventricles in experimental hypertension. , 1990, Circulation research.

[4]  A. Weyman,et al.  Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. , 1990, Circulation.

[5]  K. Weber,et al.  Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System , 1991, Circulation.

[6]  J. Zatuchni.  Atrial enlargement as a consequence of atrial fibrillation. , 1991, Circulation.

[7]  K. Weber,et al.  Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. , 1992, The Journal of laboratory and clinical medicine.

[8]  K. Weber,et al.  Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. , 1993, Journal of molecular and cellular cardiology.

[9]  M. Allessie,et al.  Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. , 1995, Circulation.

[10]  M. Russo,et al.  Histological substrate of atrial biopsies in patients with lone atrial fibrillation. , 1997, Circulation.

[11]  K. Weber,et al.  Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. , 1997, Cardiovascular research.

[12]  C. Delcayre,et al.  Myocardial Production of Aldosterone and Corticosterone in the Rat , 1998, The Journal of Biological Chemistry.

[13]  C. Delcayre,et al.  Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. , 1999, Hypertension.

[14]  R. Ardaillou.  Angiotensin II receptors. , 1999, Journal of the American Society of Nephrology : JASN.

[15]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[16]  K. Catt,et al.  International union of pharmacology. XXIII. The angiotensin II receptors. , 2000, Pharmacological reviews.

[17]  N. Dali-Youcef,et al.  Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[18]  H. Rennke,et al.  Printed in U.S.A. Copyright © 2000 by The Endocrine Society Aldosterone: A Mediator of Myocardial Necrosis and Renal Arteriopathy* , 2022 .

[19]  L. Field,et al.  Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-beta(1) transgene in the heart. , 2000, Circulation research.

[20]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[21]  F. Alla,et al.  Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES) , 2000, Circulation.

[22]  S. Dhein,et al.  Pharmacological modulation and differential regulation of the cardiac gap junction proteins connexin 43 and connexin 40 , 2002, Biology of the cell.

[23]  R. Schmieder,et al.  Aldosterone-induced cardiac damage: focus on blood pressure independent effects. , 2003, American journal of hypertension.

[24]  David R. Van Wagoner,et al.  Electrophysiological Remodeling in Human Atrial Fibrillation , 2003 .

[25]  Sander Verheule,et al.  Alterations in Atrial Electrophysiology and Tissue Structure in a Canine Model of Chronic Atrial Dilatation Due to Mitral Regurgitation , 2003, Circulation.

[26]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[27]  B. Pitt,et al.  Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[28]  K. Arakawa,et al.  Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. , 2003, Journal of the American College of Cardiology.

[29]  M. Allessie,et al.  Loss of atrial contractility is primary cause of atrial dilatation during first days of atrial fibrillation. , 2004, American journal of physiology. Heart and circulatory physiology.

[30]  H. Inoue,et al.  Tranilast attenuates myocardial fibrosis in association with suppression of monocyte/macrophage infiltration in DOCA/salt hypertensive rats , 2004, Journal of hypertension.

[31]  Sander Verheule,et al.  Increased Vulnerability to Atrial Fibrillation in Transgenic Mice With Selective Atrial Fibrosis Caused by Overexpression of TGF-β1 , 2004, Circulation research.

[32]  E. Fleck,et al.  Myocardial angiotensin receptor type 1 gene expression in a rat model of cardiac volume overload , 1997, Basic Research in Cardiology.

[33]  S. Nattel,et al.  Dissociation Between Ionic Remodeling and Ability to Sustain Atrial Fibrillation During Recovery From Experimental Congestive Heart Failure , 2004, Circulation.

[34]  M. Capecchi,et al.  Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. , 2004, The American journal of pathology.

[35]  E. Vicaut,et al.  Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. , 2005, European heart journal.

[36]  A. Zima,et al.  Endothelin-1–Induced Arrhythmogenic Ca2+ Signaling Is Abolished in Atrial Myocytes of Inositol-1,4,5-Trisphosphate(IP3)–Receptor Type 2–Deficient Mice , 2005, Circulation research.

[37]  P. Howard,et al.  Eplerenone: A Selective Aldosterone Receptor Antagonist for Patients with Heart Failure , 2005, The Annals of pharmacotherapy.

[38]  D. Reinhardt,et al.  Enhanced expression of fibrillin-1, a constituent of the myocardial extracellular matrix in fibrosis. , 2005, American journal of physiology. Heart and circulatory physiology.

[39]  R. Khokha,et al.  Myocardial extra-cellular matrix and its regulation by metalloproteinases and their inhibitors , 2005, Thrombosis and Haemostasis.

[40]  A. Shah,et al.  Aldosterone mediates angiotensin II‐induced interstitial cardiac fibrosis via a Nox2‐containing NADPH oxidase , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  P. Schirmacher,et al.  Interstitial fibrosis in the heart: differences in extracellular matrix proteins and matrix metalloproteinases in end‐stage dilated, ischaemic and valvular cardiomyopathy , 2006, Histopathology.

[42]  Ming Hua Luo,et al.  Fibrosis of Collagen I and Remodeling of Connexin 43 in Atrial Myocardium of Patients with Atrial Fibrillation , 2006, Cardiology.

[43]  S. Dhein.  Role of connexins in atrial fibrillation. , 2006, Advances in cardiology.

[44]  M. Gold,et al.  Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. , 2006, The American journal of cardiology.

[45]  Yu-ling Sun,et al.  Increased expression of extracellular matrix proteins in rapid atrial pacing-induced atrial fibrillation. , 2007, Heart rhythm.

[46]  Nolwenn Le Meur,et al.  Contrasting Gene Expression Profiles in Two Canine Models of Atrial Fibrillation , 2007, Circulation research.

[47]  Francis G Spinale,et al.  Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. , 2007, Physiological reviews.

[48]  N. Takakura,et al.  Eplerenone Attenuates Myocardial Fibrosis in the Angiotensin II-Induced Hypertensive Mouse: Involvement of Tenascin-C Induced by Aldosterone-Mediated Inflammation , 2007, Journal of cardiovascular pharmacology.

[49]  S. Nattel,et al.  Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. , 2008, Heart rhythm.

[50]  Irina Savelieva,et al.  Treatment of atrial fibrillation. , 2008, British medical bulletin.

[51]  Jens Eckstein,et al.  Mechanisms of perpetuation of atrial fibrillation in chronically dilated atria. , 2008, Progress in biophysics and molecular biology.

[52]  J. Maessen,et al.  Persistent atrial fibrillation in a goat model of chronic left atrial overload. , 2008, The Journal of thoracic and cardiovascular surgery.

[53]  G. Moe,et al.  Matrix metalloproteinase inhibition attenuates atrial remodeling and vulnerability to atrial fibrillation in a canine model of heart failure. , 2008, Journal of cardiac failure.

[54]  M. Mazzini,et al.  Pharmacotherapy for atrial arrhythmias: present and future. , 2008, Heart rhythm.

[55]  D. Callans.  Apples and oranges: comparing antiarrhythmic drugs and catheter ablation for treatment of atrial fibrillation. , 2008, Circulation.

[56]  P. Schauerte,et al.  Association of echocardiographic atrial size and atrial fibrosis in a sequential model of congestive heart failure and atrial fibrillation. , 2008, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[57]  Yao Sun,et al.  Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats , 2008, Molecular and Cellular Biochemistry.

[58]  L. Lai,et al.  Molecular genetics of atrial fibrillation. , 2008, Journal of the American College of Cardiology.

[59]  M. Young.  Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation , 2008, Current opinion in nephrology and hypertension.

[60]  T. Ishimitsu,et al.  Valsartan improves L-NAME-exacerbated cardiac fibrosis with TGF-ß inhibition and apoptosis induction in spontaneously hypertensive rats. , 2008, Journal of cardiology.

[61]  W. Han,et al.  Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs. , 2008, Chinese medical journal.

[62]  T. Borg,et al.  Cell Patterning: Interaction of Cardiac Myocytes and Fibroblasts in Three-Dimensional Culture , 2008, Microscopy and Microanalysis.

[63]  A. Struthers,et al.  A randomised, controlled, double-blind, cross-over pilot study assessing the effects of spironolactone, losartan and their combination on heart rate variability and QT dispersion in patients with chronic heart failure , 2008, Cardiovascular journal of Africa.

[64]  S. Nattel,et al.  Differential Behaviors of Atrial Versus Ventricular Fibroblasts: A Potential Role for Platelet-Derived Growth Factor in Atrial-Ventricular Remodeling Differences , 2008, Circulation.

[65]  W. Koch,et al.  An adrenal β-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo , 2009, Proceedings of the National Academy of Sciences.

[66]  D. Rifkin,et al.  Extracellular microfibrils: contextual platforms for TGFbeta and BMP signaling. , 2009, Current opinion in cell biology.

[67]  Mitsuhiko Yamada,et al.  Diacylglycerol kinase zeta inhibits G(alpha)q-induced atrial remodeling in transgenic mice. , 2009, Heart rhythm.

[68]  Peter P. Liu,et al.  Aldosterone Stimulates Elastogenesis in Cardiac Fibroblasts via Mineralocorticoid Receptor-independent Action Involving the Consecutive Activation of Gα13, c-Src, the Insulin-like Growth Factor-I Receptor, and Phosphatidylinositol 3-Kinase/Akt* , 2009, Journal of Biological Chemistry.

[69]  B. Sobel,et al.  A Profibrotic Effect of Plasminogen Activator Inhibitor Type-1 (PAI-1) in the Heart , 2009, Experimental biology and medicine.

[70]  R. Duisters,et al.  MIRNA-133 AND MIRNA-30 REGULATE CONNECTIVE TISSUE GROWTH FACTOR: IMPLICATIONS FOR A ROLE OF MIRNAS IN MYOCARDIAL MATRIX REMODELING , 2013 .

[71]  M. Allessie,et al.  Erratum to: “Mechanisms of perpetuation of atrial fibrillation in chronically dilated atria” [Prog. Biophys. Mol. Biol. 97 (2008) 435–451] , 2009 .

[72]  A. Maggioni,et al.  Valsartan for prevention of recurrent atrial fibrillation. , 2009, The New England journal of medicine.

[73]  M. Maggiolini,et al.  Endothelin-1 induces connective tissue growth factor expression in cardiomyocytes. , 2009, Journal of molecular and cellular cardiology.

[74]  S. Nattel,et al.  The Treatment of Atrial Fibrillation , 1994, Drugs.